Source: Annual Congress 2001 - Airway provocation: what's new?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. D. Brannan, M. Gulliksson, M. Kumlin, S. D. Anderson, S. E. Dahlen (Camperdown, Australia; Stockholm, Sweden). Inhalation of mannitol, used as a model for exercise-induced bronchoconstriction (EIB), causes release of leukotrienes and a mast cell marker in asthmatic subjects. Eur Respir J 2001; 16: Suppl. 31, 720

Member's Comments

No comment yet.

Related content which might interest you: Exercise-induced bronchoconstriction Source: Respipedia Article Year: 2016 EBC Cys-LT are increased in children with exercise induced bronchoconstriction (EIB) Source: Annual Congress 2004 - Monitoring childhood asthma Year: 2004 The effect of a leukotriene antagonist, pranlukast, on allergen-induced airway responses and circulating dendritic cells in subjects with atopic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003 Formoterol protects against platelet-activating factor-induced effects in asthma Source: Eur Respir J 2004; 23: 71-75 Year: 2004 Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice Source: Eur Respir J 2009; 34: 200-208 Year: 2009 Evidence of mast cell activation and leukotriene release after mannitol inhalation Source: Eur Respir J 2003; 22: 491-496 Year: 2003 Effects of roflumilast on exhaled NO, airway hyperresponsiveness, and inflammatory markers in patients with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 670s Year: 2006 The inhaled PDE4 inhibitor UK-500,001 does not significantly inhibit airway responses to allergen and histamine Source: Annual Congress 2007 - New drugs for asthma Year: 2007 Mast cell generated cyclooxygenase products protect from airway hyperresponsiveness in a model of chronic asthma Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011 Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma Source: Eur Respir J 2004; 24: 226-230 Year: 2004 Effects of salbutamol and enantiomers on allergen-induced asthmatic reactions and airway hyperreactivity Source: Eur Respir J 2005; 25: 864-872 Year: 2005 Markers of airway inflammation and airway hyperresponsiveness in patients with well-controlled asthma Source: Eur Respir J 2001; 18: 444-450 Year: 2001 Montelukast as add-on therapy to β-agonists and late airway response Source: Eur Respir J 2007; 30: 56-61 Year: 2007 Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma Source: Eur Respir J 2003; 21: 1046-1049 Year: 2003 Hypertonic saline increases secretory and exudative responsiveness of human nasal airway in vivo Source: Eur Respir J 2003; 21: 308-312 Year: 2003 Sodium cromoglycate inhibits release of mast cell mediators and bronchoconstriction following hyperpnea in athletes Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 The development of an airway hyperresponsiveness (AHR) depends on mast cells following sensitization without adjuvant Source: Annual Congress 2006 - Cellular immunology in asthma pathogenesis Year: 2006 Adenosine level in exhaled breath increases during exercise-induced bronchoconstriction Source: Eur Respir J 2005; 25: 873-878 Year: 2005 Inhibition of mast cell PGD2 release protects against mannitol-induced airway narrowing Source: Eur Respir J 2006; 27: 944-950 Year: 2006